Anti-viral azide containing compounds
    2.
    发明授权
    Anti-viral azide containing compounds 有权
    含抗病毒叠氮化合物的化合物

    公开(公告)号:US09144575B2

    公开(公告)日:2015-09-29

    申请号:US13192959

    申请日:2011-07-28

    摘要: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

    摘要翻译: 提供了使用叠氮化物修饰的生物分子如脂肪酸,碳水化合物和脂质来治疗植物,昆虫或感染病毒的动物或抑制病毒如人类免疫缺陷病毒的感染性的方法。 还提供了用叠氮化物修饰的生物分子如脂肪酸,碳水化合物或类异戊二烯脂质来标记病毒(例如人类免疫缺陷病毒)的方法。 此外,提供了利用叠氮化物修饰的生物分子如脂肪酸,碳水化合物或类异戊二烯脂质体内追踪病毒的方法。 叠氮化物修饰的生物分子可以与药学上可接受的赋形剂组合以产生药物组合物,任选地含有另一种抗病毒剂和/或递送剂,例如脂质体。

    Anti-Viral Azide Containing Compounds
    3.
    发明申请

    公开(公告)号:US20130209364A1

    公开(公告)日:2013-08-15

    申请号:US13812533

    申请日:2011-07-28

    IPC分类号: A61K31/655

    摘要: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.